Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

HPE to pursue up to $4bn from Mike Lynch estate - reports

(Sharecast News) - Hewlett Packard Enterprise (HPE) will continue its pursuit of up to $4bn in damages from the estate of the late Autonomy founder Mike Lynch, it emerged on Monday, despite his recent death. The development, reported by Fortune, was the latest chapter in a 13-year legal battle stemming from HP's troubled $11.7bn acquisition of Autonomy in 2011, which resulted in an $8.8bn write-down due to alleged accounting fraud.

In 2022, HPE won a civil trial in the UK against Lynch, with the court ruling that he was likely aware of accounting irregularities at Autonomy.

Although Lynch was acquitted of related criminal charges in the US earlier this year, he intended to appeal the civil ruling based on this verdict.

However, Lynch passed away in August in the sinking of superyacht Bayesian in poor weather off the coast of Sicily, leaving his wife Angela Bacares to potentially inherit the ongoing legal battle.

Despite speculation that HPE could drop the case to avoid negative publicity, Fortune said the company had decided to proceed.

A damages hearing took place in February, and a final judgement was expected soon.

While the court indicated that the damages would likely be less than the $4bn initially sought, HPE was reportedly committed to seeing the case through, citing its fiduciary duty to shareholders.

Lynch's estate, including his venture capital fund Invoke Capital and a 3% stake in cybersecurity firm Darktrace, was unlikely to meet the full amount of HPE's claim.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Berenberg lowers target price on Impax Asset Management
(Sharecast News) - Analysts at Berenberg lowered their target price on Impax Asset Management from 620.0p to 560.0p on Tuesday but noted that outflows had started to slow.
GSK's Arexvy provides protection over three RSV seasons, trial shows
(Sharecast News) - GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three seasons.
S&U revenue up, profitability a challenge in first half
(Sharecast News) - Motor and property finance specialist S&U reported a mixed first-half financial performance on Tuesday, after group revenue increased 9% year-on-year to £60.4m.
Loungers reports slight slowdown in LFL sales growth
(Sharecast News) - Cosy Club owner Loungers reported a slight slowdown in like-for-like sales growth on Tuesday and a jump in revenue.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.